source
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.BioPharma Dive · 2mo ago↗ source
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.BioPharma Dive · 2mo ago↗ source
- STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDAASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.STAT